Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

RADIUM-223 BOOSTS OVERALL SURVIVAL IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER AND BONE METASTASES

Radium-223 Boosts Overall Survival in Men with Castration-Resistant Prostate Cancer and Bone Metastases

Radium-223 chloride is the first skeletal-targeted therapy shown to improve survival in men with castration-resistant prostate cancer and bone metastases. At the 2012 ASCO meeting in Chicago, Dr. Chris Parker presented updated results of the ALSYMPMCA trial and announced that radium-223 chloride (Alpharadin) increased median overall survival by nearly 4 months and reduced the risk of death by 30% in this group of patients.


Slide courtesy of Cancer Treatment Reviews, 23 April 2012, © 2012, Elsevier, with permission from Even-Sapir et al. J Nucl Med 2006;47:287–297

The content of the videos, articles and all statements expressed therein do not necessarily reflect the opinions or views of the Editors, Authors or Reviewers of European Urology.